Northwire Canada EditionSunday, July 19, 2026
Sign inSubscribe
Northwire
⌕
AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0% AII 19.25 +3.9% GGA 5.95 +12.3% VM 0.140 +3.7% GSR 0.365 +1.4% QCX 0.195 +0.0% EAU 0.085 +0.0% MCM 0.310 +0.0% BAT 0.100 +5.3% SFR 0.370 +68.2% FFU 0.125 +4.2% TVI 0.045 −10.0% ZNX 0.080 +0.0% TSK 1.06 +0.9% OMM 0.050 +0.0% EMO 0.320 −7.2% MDM 0.060 +0.0%

Healthcare

Page 124
  1. Oct 02, 2025 · 08:00 · AIDR

    Rocket Doctor Partners with Remmie to Bring FDA Approved and Health Canada Cleared Smart Otoscope to Patients

    Rocket Doctor Partners with Remmie to Bring FDA Approved and Health Canada Cleared Smart Otoscope to Patients

    01
  2. Oct 02, 2025 · 08:00 · PHRM

    PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy

    PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy

    02
  3. Oct 02, 2025 · 07:57 · PHA

    Premier Health Reports AMP Decision Regarding Subsidiaries in Quebec

    Premier Health Reports AMP Decision Regarding Subsidiaries in Quebec

    03
  4. Oct 02, 2025 · 07:57 · QNTM

    Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

    Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

    04
  5. Oct 02, 2025 · 07:00 · ZYUS

    ZYUS Life Sciences Announces Activation of Two Additional Clinical Sites in Phase 2a UTOPIA-1 Cancer Pain Trial

    ZYUS Life Sciences Announces Activation of Two Additional Clinical Sites in Phase 2a UTOPIA-1 Cancer Pain Trial

    05
  6. Oct 02, 2025 · 03:05 · BNXT

    BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform

    BioNxt Reports Update on Targeted Chemotherapy Drug Delivery Platform

    06
  7. Oct 01, 2025 · 23:55 · EKG

    CardioComm Solutions Announces Royalty-Based Financing Deal

    CardioComm Solutions Announces Royalty-Based Financing Deal

    07
  8. Oct 01, 2025 · 18:02 · PHRM

    Pharmather signs definitive deal to sell ketamine ANDA

    Pharmather signs definitive deal to sell ketamine ANDA

    08
  9. Oct 01, 2025 · 17:59 · QNTM

    Quantum Biopharma appoints Antel clinical adviser

    Quantum Biopharma appoints Antel clinical adviser

    09
  10. Oct 01, 2025 · 17:08 · APLI

    Appili, Vitalex win up to $40M (U.S.) VXV-01 contract

    Appili, Vitalex win up to $40M (U.S.) VXV-01 contract

    10
  11. Oct 01, 2025 · 16:40 · SVA

    Sernova converts debt of $13.3-million into units

    Sernova converts debt of $13.3-million into units

    11
  12. Oct 01, 2025 · 08:00 · PHRM

    PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments

    PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments

    12
  13. Oct 01, 2025 · 07:17 · APLI

    Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01

    Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01

    13
  14. Oct 01, 2025 · 07:01 · SVA

    Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang

    Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang

    14
← Newer Older →